VolitionRX (VNRX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
26 Jan, 2026Executive summary
Special Meeting scheduled for March 31, 2026, to vote on two key proposals: issuing shares exceeding 20% of outstanding stock to Lind Global Asset Management XII LLC and authorizing a reverse stock split at a ratio between 1-for-5 and 1-for-20, at the board's discretion.
Board unanimously recommends voting in favor of both proposals, citing compliance with NYSE American Rule 713 and contractual obligations.
Voting can be conducted online, by phone, mail, or in person, with a record date of February 9, 2026.
Voting matters and shareholder proposals
Proposal 1 seeks approval to issue additional shares exceeding 20% of outstanding stock to Lind Global Asset Management XII LLC, potentially diluting existing shareholders but required for compliance with NYSE rules.
Proposal 2 requests authorization for a reverse stock split at a ratio between 1-for-5 and 1-for-20, to be implemented at the board's discretion, primarily to improve marketability and maintain exchange listing.
Both proposals require a majority vote of shares present or represented by proxy; abstentions count as votes against, broker non-votes have no effect.
Board of directors and corporate governance
Board of directors has full discretion to implement or abandon the reverse stock split even after shareholder approval.
No director or executive officer has a substantial interest in the reverse stock split beyond that of all shareholders.
Latest events from VolitionRX
- Shareholders to vote on major share issuance and reverse stock split to support compliance and flexibility.VNRX
Proxy Filing11 Feb 2026 - Registration enables resale of 17.97M shares, raising dilution and financial risk concerns.VNRX
Registration Filing9 Feb 2026 - Q2 revenue up 83% on record Nu.Q Vet sales; cost cuts and new funding offset ongoing losses.VNRX
Q2 20241 Feb 2026 - H3.1 testing enables rapid, predictive sepsis diagnostics with robust clinical validation.VNRX
Status Update19 Jan 2026 - Q3 2024 revenue surged 187% as global test sales grew, but financing risks persist.VNRX
Q3 202413 Jan 2026 - Licensing-driven diagnostics platform targets global cancer and sepsis markets with strong IP and key partnerships.VNRX
Corporate Presentation8 Jan 2026 - Revenue up 59% in 2024; focus on licensing, cash neutrality, and global expansion in 2025.VNRX
Q4 202419 Dec 2025 - 73,263 shares are registered for resale, with no proceeds to the company and notable business risks.VNRX
Registration Filing16 Dec 2025 - Epigenetics firm seeks to raise up to $100M for R&D and growth amid notable market risks.VNRX
Registration Filing16 Dec 2025